Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells
出版年份 2023 全文链接
标题
Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells
作者
关键词
-
出版物
New Biotechnology
Volume 77, Issue -, Pages 139-148
出版商
Elsevier BV
发表日期
2023-09-04
DOI
10.1016/j.nbt.2023.09.002
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
- (2023) Kerry A. Whalen et al. mAbs
- A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma
- (2022) Satoko Kakiuchi-Kiyota et al. LEUKEMIA
- NK‐cell exhaustion, B‐cell exhaustion and T‐cell exhaustion—the differences and similarities
- (2022) Kevin Roe IMMUNOLOGY
- Bispecific antibodies in oncology
- (2022) Arman Esfandiari et al. NATURE REVIEWS DRUG DISCOVERY
- Extramedullary disease in multiple myeloma: a systematic literature review
- (2022) Joan Bladé et al. Blood Cancer Journal
- T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities
- (2022) Patrick A. Baeuerle et al. CURRENT OPINION IN ONCOLOGY
- Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers
- (2022) Sheena Pinto et al. TRENDS IN IMMUNOLOGY
- Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
- (2022) Julia Hambach et al. Frontiers in Immunology
- Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
- (2021) Zheng Tian et al. Journal of Hematology & Oncology
- Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC
- (2021) Henk van Faassen et al. MOLECULAR PHARMACEUTICS
- Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
- (2021) Olivier Demaria et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis
- (2020) Vishesh Sarin et al. LEUKEMIA
- Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
- (2020) Omid Vafa et al. Frontiers in Oncology
- Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity
- (2020) Charles D. Murin Frontiers in Immunology
- Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
- (2019) Nathan D. Trinklein et al. mAbs
- Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
- (2019) Kristina Ellwanger et al. mAbs
- Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies
- (2019) Yining Zhao et al. CANCER BIOLOGY & THERAPY
- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells
- (2018) Yufeng Wang et al. CLINICAL CANCER RESEARCH
- CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
- (2018) Clare Y. Slaney et al. Cancer Discovery
- A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism
- (2018) Niken M. Mahaweni et al. Scientific Reports
- A single amino acid distorts the Fc γ receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a
- (2018) Jacob T. Roberts et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms
- (2017) Kirstie L. S. Cleary et al. JOURNAL OF IMMUNOLOGY
- Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action
- (2017) James I. Robinson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
- (2017) Thorsten Gantke et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Affibody Molecules in Biotechnological and Medical Applications
- (2017) Stefan Ståhl et al. TRENDS IN BIOTECHNOLOGY
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
- (2016) Lydia Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
- (2016) Wei Hseun Yeap et al. Scientific Reports
- First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule
- (2014) J. Sorensen et al. JOURNAL OF NUCLEAR MEDICINE
- A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
- (2014) Uwe Reusch et al. mAbs
- The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
- (2014) Ross Stewart et al. Journal for ImmunoTherapy of Cancer
- Ligand dimensions are important in controlling NK-cell responses
- (2010) Joanna Brzostek et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils
- (2009) Mami Shibata-Koyama et al. EXPERIMENTAL HEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started